7 results about "Acute mi" patented technology

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and / or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and / or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

The invention provides a system and method for controlling a cardiac pump to minimize myocardial oxygen consumption. Disclosed herein are various systems, devices, and methods for curing acute myocardial infarction (AMI) patients using a cardiac pump controlled in a manner that maximizes mechanical de-loading of the left ventricle and minimizes myocardial oxygen consumption (MVO2) and accordingly infarction area in the presence of cardiovascular instability, the development of subsequent heart failure is prevented. In a closed feedback system, the system may include a sensor configured to generate an output for measuring or calculating a left ventricular systolic pressure (LSVP) within a left ventricle of a heart and a controller coupled to a heart pump. The controller may be configured to measure or calculate an LVSP based on the output of the sensor, and control operation of the cardiac pump based on the measured or calculated LVSP to maximize mechanical de-loading of the left ventricle.

Disclosed herein are uses of polypeptides comprising NIMoEsh for treating diseases or conditions associated with acute myocardial infarction (AMI) in subjects in need thereof, uses of polypeptides comprising NIMoEsh for restoring cardiac function after AMI in subjects in need thereof, uses of polypeptides comprising NIMoEsh for reducing or preventing loss of cardiac function caused by AMI in subjects in need thereof, uses of polypeptides comprising NIMoEsh for reducing cardiac tissue infarction caused by AMI in subjects in need thereof, and uses of polypeptides comprising NIMoEsh for protecting cardiomyocytes from loss of function caused by AMI in subjects in need thereof. Also disclosed herein are methods for performing such treatment, restoration, reduction or prevention, reduction and / or protection, and polypeptides comprising NIMoEsh for such treatment, restoration, reduction or prevention, reduction and / or protection.

A method of providing ventricular support for patients experiencing an acute myocardial infarction (AMI) by performing a coronary intervention procedure. The method including inserting a mechanical circulatory support device into the vasculature of a patient; delivering the mechanical circulatory support device within the vasculature into a heart of the patient; operating the mechanical circulatory support device for a support period; and measuring a sympathetic nerve activity (CSNA) of the patient during the mechanical circulatory support. A reduction in the recorded CSNA levels during the mechanical circulatory support device is reduced after 60 minutes of the mechanical circulatory support by between about 40.8% to about 54.2% as compared to the CSNA levels at the initiation of the mechanical circulatory support.

A method of treating acute myocardial infarction in a patient by administering to the patient a combination of r-SAK and an antiplatelet agent such as ticagrelor. The acute myocardial infarction can be ST-elevation myocardial infarction. The patient can be one who is expected to receive percutaneous coronary intervention within 120 minutes from his or her first medical contact, e.g., one who is expected to receive percutaneous coronary intervention within 120 minutes from his or her first medical contact but more than 30 minutes from his or her first medical contact. A pharmaceutical composition for use in treating acute myocardial infarction in a patient is also provided which include r-SAK and an antiplatelet agent.

The invention provides a marker for predicting acute myocardial infarction and application of the marker. A series of novel miRNA, lncRNA and circRNA markers capable of efficiently distinguishing acute myocardial infarction super-acute stage patients and normal people are found from transcriptome data of exosomes in plasma of (6, 6 h) patients and normal people, a competitive endogenous RNA regulation and control relation network of the myocardial infarction super-acute stage is constructed, and the miRNA markers can be used for efficiently detecting the myocardial infarction super-acute stage and can be used for efficiently detecting the myocardial infarction super-acute stage. According to the kit, sensitivity and specificity diagnosis and accurate diagnosis and evaluation of acute myocardial infarction patients and potential high-risk groups in a super-acute stage within 6 hours can be realized, so that the early diagnosis rate of acute myocardial infarction can be improved, implementation of accurate medical strategies can be guided, and the treatment level of acute myocardial infarction can be improved.

This disclosure relates to various systems, devices, and methods for treating patients with acute myocardial infarction (AMI) using a heart pump that is controlled in a manner that maximizes mechanical unloading of the left ventricle and minimizes myocardial oxygen consumption (MVO2) and, accordingly, infarct size in the presence of cardiovascular instability to prevent the development of subsequent heart failure. In a closed feedback system, the system can include a sensor configured to generate an output for measuring or calculating a left ventricular systolic pressure (LSVP) within a left ventricle of the heart and a controller coupled to the heart pump. The controller can be configured to measure or calculate the LVSP based on the output of the sensor and control the operation of the heart pump based on the measured or calculated LVSP to maximize mechanical unloading of the left ventricle.